The BRAF inhibitor dabrafenib shows promising results for treatment of advanced melanoma, both alone and in combination with the MEK inhibitor trametinib, show results from two studies presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA. The BREAK-3 study compared treatment with dabrafenib with that of standard dacarbazine chemotherapy for patients with previously untreated, advanced melanoma and mutations in the BRAF gene. The researchers found that the risk for disease progression was reduced by a significant 70% in the dabrafenib group versus the dacarbazine group.

Read more in medical news

Dott. Nicola Angelotti

Medico Chirurgo - Specialista in Dermatologia e Venereologia. - Esame dermatoscopico per l’analisi dei nevi